United States · FDA National Drug Code directory
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 42385-929_80228c3a-152e-4170-9469-b4e13b137bcb
- Product NDC
- 42385-929
- Form
- TABLET, FILM COATED
- Composition / generic term
- Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate
- Labeler
- Laurus Labs Limited
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20200514
- Source listing expiry
- 20261231
Source-listed ingredients
- EFAVIRENZ — 400 mg/1
- LAMIVUDINE — 300 mg/1
- TENOFOVIR DISOPROXIL FUMARATE — 300 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 180 TABLET, FILM COATED in 1 BOTTLE (42385-929-18) · 42385-929-18
- 30 TABLET, FILM COATED in 1 BOTTLE (42385-929-30) · 42385-929-30
- 30 TABLET, FILM COATED in 1 BOTTLE (42385-929-31) · 42385-929-31
- 180 TABLET, FILM COATED in 1 BOTTLE (42385-929-82) · 42385-929-82
- 90 TABLET, FILM COATED in 1 BOTTLE (42385-929-90) · 42385-929-90
- 90 TABLET, FILM COATED in 1 BOTTLE (42385-929-91) · 42385-929-91
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →